BACKGROUND: Brain-derived neurotrophic factor (BDNF) plays a critical role in neurodevelopment and plasticity; decreased BDNF functioning may contribute to the pathogenesis of schizophrenia. However, BDNF levels are not static; in animal experiments, brain BDNF increases during spatial learning, and in clinical depression, successful antidepressant treatment raises serum BDNF. We asked: would neuroplasticity-based cognitive training in schizophrenia result in increased serum BDNF? METHODS:Fifty-six schizophrenia outpatients and 16 matched healthy comparison subjects were assessed on baseline cognitive performance and serum BDNF. Schizophrenia subjects were randomly assigned to either 50 hours (10 weeks) of computerized auditory training or a computer game control condition, followed by reassessment of cognition and serum BDNF. RESULTS: At baseline, schizophrenia participants had significantly lower-than-normal serum BDNF. Schizophrenia subjects who engaged incomputerized cognitive training designed to improve auditory processing showed significant cognitive gains and a significant increase in serum BDNF compared with subjects who played computer games. This increase was evident after 2 weeks of training, and after 10 weeks in the active condition, subjects "normalized" their mean serum BDNF levels, whereas the control group showed no change. In the active condition, change in BDNF was significantly associated with improved quality of life. CONCLUSIONS:Serum BDNF levels are significantly increased in clinically stable, chronically ill schizophrenia subjects after neuroplasticity-based cognitive training, but not after computer games. Serum BDNF levels may serve as a peripheral biomarker for the effects of intensive cognitive training and may provide a useful tool for the evaluation of cognitive enhancement methods in schizophrenia.
RCT Entities:
BACKGROUND:Brain-derived neurotrophic factor (BDNF) plays a critical role in neurodevelopment and plasticity; decreased BDNF functioning may contribute to the pathogenesis of schizophrenia. However, BDNF levels are not static; in animal experiments, brain BDNF increases during spatial learning, and in clinical depression, successful antidepressant treatment raises serum BDNF. We asked: would neuroplasticity-based cognitive training in schizophrenia result in increased serum BDNF? METHODS: Fifty-six schizophrenia outpatients and 16 matched healthy comparison subjects were assessed on baseline cognitive performance and serum BDNF. Schizophrenia subjects were randomly assigned to either 50 hours (10 weeks) of computerized auditory training or a computer game control condition, followed by reassessment of cognition and serum BDNF. RESULTS: At baseline, schizophreniaparticipants had significantly lower-than-normal serum BDNF. Schizophrenia subjects who engaged in computerized cognitive training designed to improve auditory processing showed significant cognitive gains and a significant increase in serum BDNF compared with subjects who played computer games. This increase was evident after 2 weeks of training, and after 10 weeks in the active condition, subjects "normalized" their mean serum BDNF levels, whereas the control group showed no change. In the active condition, change in BDNF was significantly associated with improved quality of life. CONCLUSIONS: Serum BDNF levels are significantly increased in clinically stable, chronically ill schizophrenia subjects after neuroplasticity-based cognitive training, but not after computer games. Serum BDNF levels may serve as a peripheral biomarker for the effects of intensive cognitive training and may provide a useful tool for the evaluation of cognitive enhancement methods in schizophrenia.
Authors: Sophia Vinogradov; Melissa Fisher; Heather Warm; Christine Holland; Margaret A Kirshner; Bruce G Pollock Journal: Am J Psychiatry Date: 2009-07-01 Impact factor: 18.112
Authors: Helton José Reis; Rodrigo Nicolato; Izabela Guimarães Barbosa; Paulo Henrique Teixeira do Prado; Marco Aurélio Romano-Silva; Antonio Lucio Teixeira Journal: Neurosci Lett Date: 2008-05-13 Impact factor: 3.046
Authors: William Berger; Akhil Mehra; Maryann Lenoci; Thomas J Metzler; Christian Otte; Gary Tarasovsky; Synthia H Mellon; Owen M Wolkowitz; Charles R Marmar; Thomas C Neylan Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2010-07-17 Impact factor: 5.067
Authors: Xiang Yang Zhang; Jun Liang; Da Chun Chen; Mei Hong Xiu; Fu De Yang; Therese A Kosten; Thomas R Kosten Journal: Psychopharmacology (Berl) Date: 2012-01-26 Impact factor: 4.530
Authors: B S Fernandes; J Steiner; M Berk; M L Molendijk; A Gonzalez-Pinto; C W Turck; P Nardin; C-A Gonçalves Journal: Mol Psychiatry Date: 2014-09-30 Impact factor: 15.992